New Scientific Approaches in Reproductive Medicine. At ReproNovo, we are passionate about bringing the dream of parenthood to life.
Location: Switzerland
Total raised: $65M
Investors 3
| Date | Name | Website |
| 10.06.2025 | Jeito Capi... | jeito.life |
| 12.06.2025 | ALSA Ventu... | alsaventur... |
| 03.06.2025 | Ysios Capi... | ysioscapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.05.2025 | Series A | $65M | - |
Mentions in press and media 12
| Date | Title | Description |
| 09.07.2026 | Three Swiss biotechs advance fertility, cancer and neuro programmes | ReproNovo, a Lausanne-based clinical-stage biopharmaceutical company founded in 2021, has dosed the first participant in NORDIC, a European Phase 2 trial of its candidate RPN-002. The randomised, placebo-controlled, double-blind study will... |
| 06.07.2026 | ReproNovo announces first participant dosed in EU Phase 2 Trial of RPN-002 for Embryo Implantation | - RPN-002 is an orally administered oxytocin receptor antagonist aiming to improve IVF/ICSI success rates - The NORDIC study marks an important step in advancing ReproNovo’s global Phase 2 pipeline acrossfertility and women’s health, with f... |
| 06.03.2026 | Investments in women-led companies set a clear record | The Swiss Startup ecosystem is clearly male dominated. According to the Startupticker database, female CEOs accounted only for 15.3% of startup foundations from 2021 to 2025. However, this share has increased compared with earlier years, w... |
| 02.10.2025 | Life sciences companies make positive progress | At Synendos Therapeutics, topline results of the phase 1 clinical trial for its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System that helps restore healthy brain fu... |
| 23.07.2025 | Three biotechs on the verge of launching potential treatments | Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, announced the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in... |
| 26.05.2025 | ReproNovo: $65 Million Series A Raised For Advancing Reproductive Medicine And Women’s Health Therapies | ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, announced the closing of a $65 million Series A financing round. The funding round was led by Jeito Capital, co-led by AXA IM A... |
| 22.05.2025 | ReproNovo's $65 Million Leap: A New Dawn for Reproductive Health | In a world where fertility rates are slipping like sand through fingers, ReproNovo emerges as a beacon of hope. This Swiss HealthTech startup, founded in 2021, has just secured $65 million in Series A financing. The funding round, led by Je... |
| 22.05.2025 | Jeito Capital leads $65 million round in ReproNovo | Jeito Capital led a $65 million Series A investment in ReproNovo ReproNovo Founded: 2021 Headquarters: Lausanne, Vaud, Switzerland See full company profile "> , a biopharma company developing treatments for reproductive medicine and... |
| 21.05.2025 | Swiss HealthTech company ReproNovo raises €57 million to tackle declining fertility rates | Lausanne-based HealthTech startup ReproNovo, a company innovating treatments for reproductive medicine and women’s health, has secured a €57 million Series A financing round. The round was led by Jeito Capital, AXA IM and M Ventures, alongs... |
| 21.05.2025 | ReproNovo Raises $65M in Series A Financing | ReproNovo, a Lausanne, Switzerland-based company dedicated to developing treatments for reproductive medicine and women’s health, raised $65M in Series A funding. The round was led by Jeito Capital, co-led by AXA IM Alts and founding invest... |
Show more